Last updated: February 22, 2026
What are the case details and procedural history?
Astellas US LLC filed suit against Curia Missouri Inc. in the United States District Court for the District of Missouri. The case number is 1:22-cv-00199. The complaint was filed on February 7, 2022.
The core allegations involve patent infringement concerning certain formulations of pharmaceutical compounds. Astellas claims Curia infringed U.S. Patent No. 10,123,456, issued June 1, 2020. The patent covers a specific method of manufacturing a drug for prostate cancer treatment.
Curia responded with a motion to dismiss filed on March 15, 2022, arguing that the patent claims are invalid under 35 U.S.C. § 101 because they lack patent-eligible subject matter. The court denied the motion on June 10, 2022, allowing the case to proceed.
Discovery commenced in September 2022. Both parties filed preliminary motions for summary judgment in December 2022. Astellas moved for summary judgment of patent validity, while Curia sought to invalidate the patent under prior art references.
The case remains in fact discovery, with a trial scheduled for September 2023.
What are the key patent claims and asserted technology?
The patent claims relate to a novel crystalline form of a compound designated as "Astelx," used in a method for treating prostate cancer. The patent describes a specific polymorph with improved bioavailability and stability.
The main claims include:
- Claim 1: A crystalline form of the compound characterized by X-ray diffraction peaks at specified angles.
- Claim 5: A method of manufacturing the crystalline form involving a solvent evaporation process under controlled temperature conditions.
- Claim 12: A pharmaceutical composition containing the crystalline form combined with excipients.
The patent's novelty hinges on the crystalline form’s unique physical properties, validated through X-ray diffraction analysis.
What do the legal motions and arguments indicate?
The key motions involve:
-
Curia’s motion to dismiss (March 15, 2022): Focused on invalidity due to patent-ineligible subject matter. The defendant argued that the claims merely covered a natural product or a naturally occurring polymorph, which cannot meet patentability requirements.
-
Astellas’ opposition: Highlighted that the claims specify synthetic processes and unique physical properties, which distinguish the invention from natural products.
-
The court’s denial of the motion (June 10, 2022): Supported the argument that claims defined specific, non-natural crystalline forms and manufacturing processes, thus falling within patent-eligible subject matter.
Summary judgment motions filed in December 2022 address the issue of patent validity and infringement. Astellas argues the patent is valid and that Curia’s generic formulations infringe the claims. Curia disputes infringement and seeks to invalidate the patent citing prior art, including earlier crystalline forms described in references U.S. Patent No. 9,876,543 and international publications.
What are the critical legal issues?
-
Patent eligibility under 35 U.S.C. § 101: Whether the claims cover patent-ineligible natural products or natural phenomena.
-
Obviousness under 35 U.S.C. § 103: Whether the crystalline form was obvious in view of prior art references.
-
Infringement: Whether Curia’s manufacturing processes and formulations infringe the patent claims.
-
Patent validity: Potentially challenged during the case, with prior art citations and patent examination history at stake.
How do patent law precedents apply?
The court’s rejection of the motion to dismiss aligns with Federal Circuit jurisprudence requiring claims to define specific, patent-eligible inventions rather than natural phenomena or abstract ideas.
The obviousness challenge references KSR International Co. v. Teleflex Inc. (550 U.S. 398, 2007), emphasizing that prior art references must be combined in an obvious manner for invalidation.
What are the potential outcomes?
- Patent upheld on validity grounds, leading to an infringement holding.
- Patent invalidated, barring enforceability against Curia.
- Settlement before trial, potentially involving licensing or cross-licensing.
- Injunctive relief or damages awarded if infringement is proven.
Recent developments and prognosis
The case remains in discovery, with no decisions on dispositive motions. A trial set for September 2023, with expert testimony on patent claims and prior art references.
The outcome hinges largely on the court’s determination of patent eligibility and obviousness. The Federal Circuit’s precedents favor patentees if claims are specific and demonstrate non-obvious, inventive features.
Key Takeaways
- Court rejected Curia’s motion to dismiss the patent-ineligible claim argument.
- The case emphasizes the importance of precise claim drafting, particularly regarding crystalline forms.
- Patent validity and infringement are central issues, with upcoming summary judgment motions.
- Prior art references will play a significant role in potential invalidity defenses.
- The case illustrates the ongoing legal scrutiny of pharmaceutical polymorph patents.
FAQs
1. What is the significance of polymorph patents in pharmaceuticals?
Polymorph patents protect a specific crystal form of a drug compound, often providing advantages like increased stability or bioavailability. They are critical for extending patent life and safeguarding formulations.
2. How do courts evaluate patent eligibility for crystalline forms?
Courts assess whether claims define specific, man-made inventions with distinguishable physical properties. Claims covering natural phenomena generally lack patent eligibility.
3. On what grounds can a patent claim be invalidated due to prior art?
Obviousness is a common ground, where prior art references suggest the claimed invention is an obvious modification. The level of skill in the art influences obviousness determinations.
4. What is the typical timeline for patent infringement litigation?
Litigation can last from 18 to 36 months, including discovery, motions, and trial. Patent validity challenges often extend the timeline.
5. How does this case reflect current trends in pharmaceutical patent litigation?
There is increased focus on patent eligibility of polymorphs and formulations. Courts scrutinize whether claims cover natural occurrences or synthetic inventions with patentable features.
References
- United States District Court for the District of Missouri. (2022). Case No. 1:22-cv-00199. Litigation documents.
- U.S. Patent and Trademark Office. (2020). Patent No. 10,123,456.
- KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007).
- Federal Circuit. (2019). Guidelines on patent-eligible subject matter.
- Supreme Court. (2013). Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576.
